Cargando…
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies...
Autores principales: | Guo, Haiyang, Zhang, Jun, Qin, Chao, Yan, Hang, Liu, Tao, Hu, Haiyang, Tang, Shengjie, Tang, Shoujun, Zhou, Haining |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600447/ https://www.ncbi.nlm.nih.gov/pubmed/36291069 http://dx.doi.org/10.3390/cells11203200 |
Ejemplares similares
-
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
por: Tang, Shengjie, et al.
Publicado: (2022) -
miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
por: Yan, Hang, et al.
Publicado: (2022) -
Development and validation of a novel prognostic model for patients with surgically resected esophageal squamous cell carcinoma
por: Hu, Haiyang, et al.
Publicado: (2022) -
Hybrid treatment of an unusual traumatic aortic arch rupture with pseudoaneurysm: a case report
por: Tang, Shoujun, et al.
Publicado: (2019) -
Current status of and progress in the treatment of malignant pleural effusion of lung cancer
por: Zhao, Yuhua, et al.
Publicado: (2023)